[1]

Huang ML, Yan CJ, Xiao JJ, et al. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in northwest China[J/OL]. Diagn Pathol, 2019, 14(1): 74[2019-08-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626378. DOI: 10.1186/s13000-019-0849-6.
[2] Xing MZ, Alzahrani AS, Carson KA, et al.  Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer[J]. JAMA, 2013, 309(14): 1493-1501.   doi: 10.1001/jama.2013.3190
[3] Pessôa-Pereira D, Medeiros MFDS, Lima VMS, et al.  Association between BRAF (V600E) mutation and clinicopathological features of papillary thyroid carcinoma: a Brazilian single-centre case series[J]. Arch Endocrinol Metab, 2019, 63(2): 97-106.   doi: 10.20945/2359-3997000000120
[4] Xing MZ, Westra WH, Tufano RP, et al.  BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2005, 90(12): 6373-6379.   doi: 10.1210/jc.2005-0987
[5] Trovisco V, Soares P, Preto A, et al.  Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness[J]. Virchows Arch, 2005, 446(6): 589-595.   doi: 10.1007/s00428-005-1236-0
[6] Elisei R, Viola D, Torregrossa L, et al.  The BRAFV600E mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study[J]. J Clin Endocrinol Metab, 2012, 97(12): 4390-4398.   doi: 10.1210/jc.2012-1775
[7] Haugen BR, Alexander EK, Bible KC, et al.  2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133.   doi: 10.1089/thy.2015.0020
[8] 王维娜, 曹燕珍, 陈海霞, 等.  甲状腺乳头状癌BRAF V600E基因突变与临床病理特征相关性研究[J]. 新疆医科大学学报, 2018, 41(1): 79-82.   doi: 10.3969/j.issn.1009-5551.2018.01.019
Wang WN, Cao YZ, Chen HX, et al.  Correlation between BRAF V600E mutation and clinicopathologic features of papillary thyroid carcinoma[J]. J Xinjiang Med Univ, 2018, 41(1): 79-82.   doi: 10.3969/j.issn.1009-5551.2018.01.019
[9] Guan HX, Ji MJ, Bao R, et al.  Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2009, 94(5): 1612-1617.   doi: 10.1210/jc.2008-2390
[10] Seo JY, Choi JR, Moon HJ, et al.  Clinical implication of highly sensitive detection of the BRAFV600E mutation in fine-needle aspirations according to the thyroid Bethesda system in patients with conventional papillary thyroid carcinoma[J]. Ann Otol Rhinol Laryngol, 2015, 124(5): 392-399.   doi: 10.1177/0003489414560433
[11] Giordano D, Frasoldati A, Kasperbauer JL, et al.  Lateral neck recurrence from papillary thyroid carcinoma: predictive factors and prognostic significance[J]. Laryngoscope, 2015, 125(9): 2226-2231.   doi: 10.1002/lary.25094
[12] Palona I, Namba H, Mitsutake N, et al.  BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor κB activation[J]. Endocrinology, 2006, 147(12): 5699-5707.   doi: 10.1210/en.2006-0400
[13] Zhou DH, Li Z, Bai XF.  BRAFV600E and RET/PTC promote proliferation and migration of papillary thyroid carcinoma cells in vitro by regulating nuclear factor-κB[J]. Med Sci Monit, 2017, 23: 5321-5329.   doi: 10.12659/msm.904928
[14]

Revilla G, Corcoy R, Moral A, et al. Cross-talk between inflammatory mediators and the epithelial mesenchymal transition process in the development of thyroid carcinoma[J/OL]. Int J Mol Sci, 2019, 20(10): 2466[2019-08-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566886. DOI: 10.3390/ijms20102466.
[15] Sun Y, Yu S, Liu YY, et al.  Expression of miRNAs in papillary thyroid carcinomas is associated with BRAF mutation and clinicopathological features in Chinese patients[J]. Int J Endocrinol, 2013, 2013: 128735-.   doi: 10.1155/2013/128735
[16] Li BL, Lu Y, Yu LH, et al.  miR-221/222 promote cancer stem-like cell properties and tumor growth of breast cancer via targeting PTEN and sustained Akt/NF-κB/COX-2 activation[J]. Chem Biol Interact, 2017, 277: 33-42.   doi: 10.1016/j.cbi.2017.08.014
[17] Galardi S, Mercatelli N, Farace MG, et al.  NF-κB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells[J]. Nucleic Acids Res, 2011, 39(9): 3892-3902.   doi: 10.1093/nar/gkr006
[18] Algeciras-Schimnich A.  Thyroglobulin measurement in the management of patients with differentiated thyroid cancer[J]. Crit Rev Clin Lab Sci, 2018, 55(3): 205-218.   doi: 10.1080/10408363.2018.1450830
[19] 杨珂, 梁智勇, 孟超, 等.  甲状腺乳头状癌BRAFV600E基因突变与远处转移灶摄碘能力的相关性研究[J]. 中华核医学与分子影像杂志, 2014, 34(4): 287-291.   doi: 10.3760/cma.j.issn.2095-2848.2014.04.005
Yang K, Liang ZY, Meng C, et al.  Relationship between BRAFV600E mutation and radioactive iodine uptake in distant metastases from papillary thyroid cancer[J]. Chin J Nucl Med Mol Imaging, 2014, 34(4): 287-291.   doi: 10.3760/cma.j.issn.2095-2848.2014.04.005
[20] Durante C, Puxeddu E, Ferretti E, et al.  BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism[J]. J Clin Endocrinol Metab, 2007, 92(7): 2840-2843.   doi: 10.1210/jc.2006-2707
[21] Bastos AU, Oler G, Nozima BH, et al.  BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma[J]. Eur J Endocrinol, 2015, 173(4): 525-540.   doi: 10.1530/EJE-15-0254
[22]

Kotlarek M, Kubiak A, Czetwertynska M, et al. The rs2910164 genetic variant of miR-146a-3p is associated with increased overall mortality in patients with follicular variant papillary thyroid carcinoma[J/OL]. Int J Mol Sci, 2018, 19(3): 655[2019-08-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877516. DOI: 10.3390/ijms19030655..
[23]

Chou CK, Liu RT, Kang HY. MicroRNA-146b: a novel biomarker and therapeutic target for human papillary thyroid cancer[J/OL]. Int J Mol Sci, 2017, 18(3): 636[2019-08-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372649. DOI: 10.3390/ijms18030636..
[24] Gómez-Pérez AM, Cornejo Pareja IM, Garcia Alemán J, et al.  New molecular biomarkers in differentiated thyroid carcinoma: impact of miR-146, miR-221 and miR-222 levels in the evolution of the disease[J]. Clin Endocrinol (Oxf), 2019, 91(1): 187-194.   doi: 10.1111/cen.13972